Drug Cocktail Optimization in Chemotherapy of Cancer
暂无分享,去创建一个
Saskia Preissner | Mathias Dunkel | Robert Preissner | Michael F. Hoffmann | Sarah C. Preissner | R. Preissner | N. Genov | Mathias Dunkel | S. Preissner | Nikolai Genov | Wen Wei Rong | Karlheinz Seeger | K. Seeger | W. Rong
[1] René H. Levy,et al. Metabolic Drug Interactions , 2000 .
[2] U. Fuhr,et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. , 2001, International journal of clinical pharmacology and therapeutics.
[3] X. J. Zhou,et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.
[4] H. Kroemer,et al. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide , 1999, Cancer Chemotherapy and Pharmacology.
[5] Mark Gerstein,et al. Data Mining on the Web , 2006, Science.
[6] F. Giles,et al. In Vitro Evaluation of Cytochrome P450-mediated Drug Interactions between Cytarabine, Idarubicin, Itraconazole and Caspofungin , 2004, Hematology.
[7] R. Gray,et al. Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study , 2010, Breast Cancer Research.
[8] Roland Mertelsmann,et al. Das Blaue Buch , 2010 .
[9] D. Nelson,et al. Cytochrome P450 nomenclature, 2004. , 2006, Methods in molecular biology.
[10] R. Peng,et al. In vitro metabolic characteristics of cytochrome P-450 2A6 in Chinese liver microsomes. , 2002, Acta pharmacologica Sinica.
[11] Z. Dvořák,et al. Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. , 2009, Chemico-biological interactions.
[12] N. Pyszczynski,et al. Pharmacokinetic and Pharmacoimmunodynamic Interactions Between Prednisolone and Sirolimus in Adrenalectomized Rats , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[13] Eric F. Johnson,et al. Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. , 2003, Archives of biochemistry and biophysics.
[14] HighWire Press,et al. Drug metabolism and disposition : the biological fate of chemicals. , 1973 .
[15] O Pelkonen,et al. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. , 2000, American journal of respiratory cell and molecular biology.
[16] M. Keating,et al. Predicting survival in chronic lymphocytic leukemia , 2012, Expert review of anticancer therapy.
[17] S. Meyer,et al. Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[18] Edward C. Bell,et al. Complementary and Alternative Medicine: Lack of Pharmacokinetic Interaction Between St. John's Wort and Prednisone , 2007, The Annals of pharmacotherapy.
[19] S. Bates,et al. Progress towards personalized medicine. , 2010, Drug discovery today.
[20] P. Neuvonen,et al. Cytochrome P450‐inducing antiepileptics increase the clearance of vincristine in patients with brain tumors , 1999, Clinical pharmacology and therapeutics.
[21] B. K. Park,et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.
[22] Grishanova AIu,et al. [Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice]. , 2003 .
[23] U. Christians,et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[24] J. Pascussi,et al. Induction of CYP2C genes in human hepatocytes in primary culture. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[25] Tim Berners-Lee,et al. Publishing on the semantic web , 2001, Nature.
[26] G. Murray,et al. Tumour cytochrome P450 and drug activation. , 2002, Current pharmaceutical design.
[27] P. Farmer,et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.
[28] M. Angalakuditi,et al. Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing , 2011, ClinicoEconomics and outcomes research : CEOR.
[29] G. F. Weber,et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.
[30] D. Nelson,et al. Cytochrome P450 nomenclature. , 1998, Methods in molecular biology.
[31] J. Pascussi,et al. INDUCTION OF CYP 2 C GENES IN HUMAN HEPATOCYTES IN PRIMARY CULTURE , 2001 .
[32] Jürg Müller,et al. Two types of cytochrome P-45011β in rat adrenals: Separate regulation of gene expression , 1993, Molecular and Cellular Endocrinology.
[33] Jennifer B Dennison,et al. SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5 , 2006, Drug Metabolism and Disposition.
[34] Magnus Ingelman-Sundberg,et al. The human genome project and novel aspects of cytochrome P450 research. , 2005, Toxicology and applied pharmacology.
[35] M. Waterman,et al. Dexamethasone inhibits corticotropin-induced accumulation of CYP11A and CYP17 messenger RNAs in bovine adrenocortical cells. , 1993, Molecular endocrinology.
[36] D. Waxman,et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. , 1997, Cancer research.
[37] S. Lydersen,et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia , 2011, Pediatric blood & cancer.
[38] Hongbing Wang,et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[39] K. Schmiegelow,et al. Pharmacogenetics Influence Treatment Efficacy in Childhood Acute Lymphoblastic Leukemia , 2008, Journal of pediatric hematology/oncology.
[40] Renata C. Geer,et al. The NCBI BioSystems database , 2009, Nucleic Acids Res..
[41] H. Yamazaki,et al. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities. , 2011, Current drug metabolism.
[42] Wanjin Tang,et al. Hormonal regulation of the human sterol 27-hydroxylase gene CYP27A1. , 2003, The Biochemical journal.
[43] X. J. Zhou,et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.
[44] S. Hall,et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.
[45] I. Roots,et al. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. , 2003, European journal of pharmacology.
[46] G. Hortobagyi,et al. Effect of CYP2D6 polymorphisms on breast cancer recurrence , 2012, Cancer.
[47] J. Schellens,et al. Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer , 2006, Clinical pharmacokinetics.
[48] F. Komada,et al. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. , 2003, Biological & pharmaceutical bulletin.
[49] H. Ueyama,et al. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone , 2004, Molecular Biology Reports.
[50] E. Begg,et al. Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice , 2006, Pharmacological Reviews.
[51] D. Waxman,et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[52] Wendy Hall,et al. Creating a Science of the Web , 2006, Science.
[53] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[54] S. Davies,et al. Pharmacogenetics of acute lymphoblastic leukemia , 2004, Current opinion in hematology.